Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results , but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15 per share was 20.5% ...

PacBio said it expects new Vega shipments to offset year-over-year declines in Revio instrument sales—while currently installed Revios continue to bring in about $236,000 apiece in annual ...

Pacific Biosciences' Q4'24 results missed estimates. Growth in genetic data usage noted, but research funding uncertainties pose risks. See more on PACB stock here.

The global SMRT market, valued at $2.74 billion in 2023, is projected to reach $4.14 billion by 2031, witnessing a CAGR of 5.3%. Additionally, PacBio has expanded its offerings by integrating ...

Gene sequencing equipment maker PacBio plans to cut around 120 jobs and lower expenses due to fresh tariffs and reduced funding for federal health agency National Institutes of Health (NIH), it ...

PacBio said it is solidifying and expanding its distribution agreement with a local company, with plans to grow the footprint of its hi-fi long-read sequencers among both clinical and research labs.

While Pacific Biosciences' earnings were beat, shrinking sales, high debt, and poor macro environment do not inspire confidence. Read why PACB is a Strong Sell.